|
WO2019155416A2
|
|
A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
|
|
WO2019111193A1
|
|
A stable pharmaceutical composition comprising penicillamine
|
|
WO2019106586A1
|
|
A stable glucagon formulation for emergency treatment of hypoglycemia
|
|
WO2019030645A1
|
|
Pharmaceutical composition comprising eliglustat
|
|
WO2019025934A1
|
|
A stable oral pharmaceutical composition of pimavanserin
|
|
WO2019016673A2
|
|
A stable oral pharmaceutical composition of imatinib
|
|
US2020337998A1
|
|
Gastroretentive dosage forms for sustained drug delivery
|
|
WO2018217735A2
|
|
High-concentration fulvestrant compositions
|
|
US2018296486A1
|
|
Food independent immediate release drug formulation with abuse deterrence and overdose protection
|
|
WO2018132725A1
|
|
Opioid agonist / antagonist combination dosage forms
|
|
WO2017192608A1
|
|
Immediate release drug formulation combining opioid and nonopioid analgesics with abuse deterrence and overdose protection
|
|
CA3013326A1
|
|
Extended release drug formulation with overdose protection and abuse deterrence
|
|
US2018303757A1
|
|
Enhanced abuse-deterrent formulations of oxycodone
|
|
WO2017059374A1
|
|
Overdose protection and abuse deterrent immediate release drug formulation
|
|
US2017071915A1
|
|
Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
|
|
WO2015148538A1
|
|
Method of manufacturing fine particles suitable for orally disintegrating pharmaceutical dosage forms
|
|
WO2014205226A1
|
|
Self-nanoemulsion of poorly soluble drugs
|
|
AU2013361292A1
|
|
Supersaturated stabilized nanoparticles for poorly soluble drugs
|
|
WO2014100418A2
|
|
Orally disintegrating tablet formulation for enhanced bioavailability
|
|
US2014378948A1
|
|
Medicament applicator
|
